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Abstract Tumors of the pediatric facial skeleton represent a
major challenge in clinical practice because they can lead to
functional impairment, facial deformation, and long-term dis-
figurement. Their treatment often requires a multidisciplinary
approach, and radiologists play a pivotal role in the diagnosis
and management of these lesions. Although rare, pediatric tu-
mors arising in the facial bones comprise a wide spectrum of
benign and malignant lesions of osteogenic, fibrogenic, hema-
topoietic, neurogenic, or epithelial origin. The more common
lesions include Langerhans cell histiocytosis and osteoma,
while rare lesions include inflammatory myofibroblastic and
desmoid tumors; juvenile ossifying fibroma; primary
intraosseous lymphoma; Ewing sarcoma; and metastases to
the facial bones from neuroblastoma, Ewing sarcoma, or reti-
noblastoma. This article provides a comprehensive approach
for the evaluation of children with non-odontogenic tumors of
the facial skeleton. Typical findings are discussed with empha-
sis on the added value of multimodality multiparametric im-
aging with computed tomography (CT), magnetic resonance
imaging (MRI) with diffusion-weighted imaging (DWI), posi-
tron emission tomography CT (PET CT), and PET MRI. Key
imaging findings and characteristic histologic features of be-
nign and malignant lesions are reviewed and the respective role
of each modality for pretherapeutic assessment and post-
treatment follow-up. Pitfalls of image interpretation are ad-
dressed and how to avoid them.
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Introduction and background
Tumors arising in the pediatric facial skeleton represent a formi-
dable challenge in clinical practice because of the complex anat-
omy of the head and neck (HN) and because of facial develop-
ment during this time span. Although rare, these conditions in-
clude a broad spectrum of lesions with a varying degree of ma-
lignant potential [1–4]. Their true incidence is difficult to estab-
lish due to the paucity of reports in the literature and because
most published articles are either isolated case reports or series
dealing with a specific histological diagnosis. Depending on le-
sion origin, tumors can be classified as primarily originating in
the facial bones or as metastases to the facial skeleton. Tumors
arising within the jaws can be further subdivided into
odontogenic and non-odontogenic. Most pediatric tumors of
the facial bones are of non-odontogenic origin [2, 3]. They tend
to occur in themandible in the 11–15-year-old age group, and the
majority (70–90%) are benign [2, 3].
Symptoms are often non-specific and include swelling, facial
asymmetry, induration, pain, paresthesia, bleeding, or increased
tooth mobility [1]. However, due to the slow growth rate, most
lesions do not cause pain. In a recent article reviewing the clinical
presentation, management, and outcome of children with
odontogenic and non-odontogenic jaw tumors seen over a period
of 20 years, the authors found that as many as 25% of patients
were asymptomatic, the tumors being diagnosed only by imag-
ing [1]. Irrespective of origin and dignity, prompt workup with
cross-sectional imaging and—whenever necessary—biopsy are
crucial for a successful multidisciplinary management [1–4].
Multidisciplinary treatment requires a close collaboration be-
tween pediatricians, radiologists, medical oncologists, maxillofa-
cial and HN surgeons, radiotherapists, and pathologists. In addi-
tion, long-term follow-up is necessary in many pediatric cases
because of subsequent facial deformity or functional impairment
at the adult age. Facial deformity and functional impairment may
be the result of asymmetric facial growth related to the lesion
itself or to its treatment.
Radiologists evaluating children with facial lesions must be
aware of the typical imaging findings of benign and malignant
tumors and their mimics, characteristic patterns of tumor spread,
and potential pitfalls of image interpretation; furthermore, they
must be confident when recommending biopsy or a Bwait-and-
see^ policy as biopsy may result in unnecessary morbidity
whereas a wait-and-see policy may prove to be hazardous. In
order to achieve these goals, multimodality imaging is often
required and integration of multiple and sometimes discordant
findings into a comprehensive radiological report is essential.
To the best of our knowledge, a comprehensive review of
multiparametric and multimodality imaging features of these rare
tumors has not yet been published. The purposes of this article are
to review typical imaging findings and discuss the added value of
multimodality imaging with computed tomography (CT), mag-
netic resonance imaging (MRI) including diffusion-weighted im-
aging (DWI), positron emission tomography CT (PET CT), and
PET MRI. We highlight key imaging features of benign and
malignant tumors based on radiologic-pathologic correlation,
and we discuss potential pitfalls of image interpretation caused
by overlapping imaging features.
Imaging techniques
High-resolution, thin-slice MRI and CT are the standard of care
for the assessment of facial lesions, whereas ultrasonography
(US) is the preferred method for evaluating superficial soft tissue
swellings caused by extracranial HN masses. The choice of the
most appropriate imaging technique depends on the individual
clinical status: a soft, mobile, well-delineated, and compressible
swelling will often be imaged with US first, whereas an indurat-
ed, poorly defined soft tissue lesion adherent to bone will be
imaged with MRI and/or CT. MRI is preferred over CT because
of its higher soft tissue contrast and higher specificity. The MRI
protocol should routinely include T1- and T2-weighted se-
quences with or without fat saturation and a DWI sequence with
at least two b values (b = 0 and b = 1000) for mono-exponential
fitting. The apparent diffusion coefficient (ADC) is a metric used
for quantification. In the extracranial HN, restricted diffusion
(high signal on b 1000 and low ADC values) is typically seen
in malignant hypercellular tumors, in abscesses, in thrombi, and
in Warthin tumors, whereas the absence of restriction is the hall-
mark of benign tumors. The reported mean ADC values for
malignant pediatric tumors are below 0.8 × 10−3 mm2/s, whereas
benign tumors (with the exception of fibroma) have ADC values
in the range of 1.25–1.6 × 10−3 mm2/s; the ADC values of cystic
lesions are in the range of 1.9–2.2 × 10−3 mm2/s [5]. Contrast-
enhancedMRI (CEMRI) images should be acquired whenever a
tumor or a vascular lesion is suspected, to improve lesion char-
acterization and to detect perineural spread. Nevertheless, as the
information obtained by MRI and CT is often complementary,
our institutional practice includes an MRI examination (if possi-
ble without sedation) followed by a low-dose CT protocol to
assess bony structures for improved lesion characterization or
for presurgical planning. As suggested in the literature [6], the
radiation dose delivered by CT should be minimized in accor-
dance to theAs LowAsReasonablyAchievable (ALARA) prin-
ciple, in particular as children have a higher risk for expressing
radiation effects during their life span than adults [6]. Therefore,
whenever CT is needed, the size of the scanned body region
should be limited to the minimum necessary and a low-dose
protocol should be applied. Due to its low radiation dose and
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high resolution for bony structure abnormalities, cone beam CT
(CBCT) can be used as an alternative to CT. However, CBCT
scans with adult settings may result in excessive radiation to
children scanned with such default adult settings [7]. Therefore,
collimation should be used whenever possible to reduce the ra-
diation dose. As with CT, the use of CBCT scans should be
justified on a case-by-case basis [7].
F18-Fluoro-deoxy-D-glucose (FDG) PET CT is a rapid and
reliable technique for the initial assessment and follow-up of
pediatric and adult tumors originating in the HN [8–13]. As
FDG is taken up by all cells with an increased glucose metab-
olism, uptake in the normal lymphoid tissue ofWaldeyer’s ring,
salivary glands, and brown fat, as well as inflammatory and
infectious conditions or granulomatous diseases, may occasion-
ally lead to false-positive assessments [13]. On the contrary,
small lesion size and vicinity to anatomic areas with high-
glucose metabolism, such as the brain, can lead to false-
negative interpretations unless correlation with MRI or CT is
obtained [13]. As an alternative to PET CT, the recently intro-
duced hybrid PETMRI technology has emerged as a promising
tool in adult and pediatric oncology [14–17]. It has the advan-
tage of offering decreased radiation exposure in addition to
combined anatomic, functional, and metabolic information.
PETMRI is technically feasible in children as young as 6 years
of age without general anesthesia, showing comparable accura-
cy to PET CT [17]. However, child-specific patient preparation
procedures are mandatory in order to obtain good-quality ex-
aminations. Staging and follow-up of pediatric lymphoma have
been recognized as a key application of whole-body PET MRI
[17, 18].
Advanced post-processing techniques are gaining increasing
popularity for presurgical assessment, for treatment planning,
and for post-treatment follow-up. Fusion of PET and CT data is
routinely performed to combine anatomic and metabolic infor-
mation. Fusion of PET or DWI images and anatomic MRI se-
quences can be easily obtained with hybrid PET MRI systems,
whereas, if PET data are acquired independently fromMRI data,
multimodality fusion can be obtained by commercially available
software algorithms. These algorithms also enable fusion ofMRI
and CT data to enhance simultaneous soft tissue and osseous
visualization. Tumor volumetry can be obtained with
semiautomated or automated segmentation methods, and multi-
layer 3D reconstructions depicting the tumor, major arteries, and
veins, as well as skull base foramina and cranial nerves, are
further examples of advanced post-processing techniques. In
our institution, we routinely perform these techniques whenever
complex craniofacial tumor resection is planned.
Primary intraosseous tumors
Primary intraosseous tumors of non-odontogenic origin aris-
ing in children and adolescents include osteoma and
osteoblastoma, Langerhans cell histiocytosis, desmoplastic fi-
broma, inflammatory myofibroblastic tumor, juvenile ossify-
ing fibroma, Ewing sarcoma and osteosarcoma, and primary
intraosseous lymphoma.
Osteoma
Craniofacial osteomas are benign, slowly growing tumors that
aremainly seen in the paranasal sinuses, jaws, and outer table of
the skull vault. They represent 3% of all benign paranasal sinus
tumors and are most often encountered after 40 years of age.
Although osteomas are commonly found on CT examinations
of the paranasal sinuses in adults, they are very uncommon in
the pediatric population [19, 20]. The etiology of osteoma is
unclear, and developmental, traumatic, or infective origins have
been suggested [20]. Multiple osteomas are part of Gardener
syndrome. Histologically, osteomas can be divided into (1) ivo-
ry or compact osteomas composed of mature lamellar bone
without Haversian canals and without fibrous components
and (2) trabecular or spongious osteomas composed of cancel-
lous trabecular bone surrounded by a cortical bone margin.
Some tumors show mixed or overlapping features. Most oste-
omas are usually smaller than 20mm in diameter although giant
osteomas (>30 mm) have been reported [21]. Clinically, most
craniofacial osteomas are asymptomatic and they are usually
detected by cross-sectional imaging. However, when large, they
may result in facial asymmetry, pain (due to nerve compres-
sion), headache, diplopia, exophthalmos and excessive lacrima-
tion (due to extension into the orbit), sinusitis and mucocele
(due to obstruction of the sinonasal drainage pathways), cere-
brospinal fluid rhinorrhea, and dental malocclusion and trismus
(when the mandible or maxilla is involved). In children and
adolescents, craniofacial osteomas tend to arise in the frontal
or ethmoid sinuses at the junction between endochondral and
membranous bones. According to the literature, nearly 40% of
sino-orbital osteomas have histologic features similar to
osteoblastomas (immature bone with enlarged osteoblasts and
fibrovascular stroma); therefore, the term Bsino-orbital osteoma
with osteoblastoma like features^ has been recommended [22].
Some authors have even suggested that probablymany reported
sino-nasal osteoblastomas are actually osteomas with
osteoblastoma-like features [23]. The CT and MRI aspect of
sino-nasal osteoma is straightforward and reflects the underly-
ing histology (Fig. 1). On CT, ivory osteomas characteristically
appear as very dense calcified lesions, whereas trabecular oste-
omas may demonstrate bony marrow (Fig. 1). Occasionally,
osteomas are less dense and they display a ground glass appear-
ance at CT. As the ivory osteoma portions tend to have very low
signal intensity on all MRI sequences, in the absence of CT,
these low-signal-intensity areas can be misinterpreted as air
within the paranasal sinuses or nasal fossae (Fig. 1).
Correlation with CT or CBCT is, therefore, mandatory. In tra-
becular osteomas, due to the variable presence of fatty marrow
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and red marrow, the signal intensity can be quite variable on T1-
weighted and T2-weighted images, whereas after administration
of gadolinium chelates, moderate to strong enhancement is ob-
served. In rare cases, chronic osteomyelitis with button seques-
trum (devascularized bone surrounded by a lucent rim) canmimic
osteoma at cross-sectional imaging and only histologic analysis
allows the correct diagnosis (Fig. 2). As opposed to osteomas,
which typically present polypoid intraorbital or intrasinonasal
growth, osteoid osteoma, which is exceptionally rare in the cra-
niofacial bones, presents with a central nidus surrounded by a
sclerotic peripheral zone [22]. Surgery via an endoscopic ap-
proach is the treatment of choice in large osteomas and
osteoblastomas while small asymptomatic osteomas are followed
clinically and with cross-sectional imaging. As endoscopic proce-
dures tend to be more difficult in children due to the small ana-
tomic structures, a neuronavigation-guided endoscopic procedure
while being prepared to perform an open approach is preferred
[20]. More recently, radiofrequency ablation has been shown to
provide safe, minimally invasive, and effective long-lasting treat-
ment of osteoid osteoma arising in the spine, periarticular/
intraarticular, and lower limb regions [24]. Although this
technique is associated with reduced health care resources and
although it has been recommended as the treatment of choice
for osteoid osteoma of the limbs in children and adolescents
[25], its use in osteomas arising in the craniofacial skeleton has
not been reported. CT and CBCT are recommended for follow-
up, if necessary.
Langerhans cell histiocytosis
Langerhans cell histiocytosis (LCH) is a rare disease with an
incidence of 0.5–5 cases per million persons per year [26–28].
It comprises three entities: (1) eosinophilic granuloma (EG),
which is the benign unifocal form of LCH; (2) Hand-
Schüller-Christian triad, which is the combination of diabetes
insipidus, lytic bone lesions, and exophthalmos; and (3) multi-
focal multisystem LCR, also called Abt-Letterer-Siwe disease,
which is a fulminant disease with abdominal involvement and
poor prognosis. The pathogenesis of LCH is not known, and
some arguments support the reactive nature while other argu-
ments, such as the presence of BRAF V600E and MAP2K1
gene mutations, rather suggest a neoplastic process [28]. LCH
Fig. 1 Two histologically proven cases of osteoma. Ethmoid sinus
osteoma in a 15-year-old boy with left orbital pain and recurrent
sinusitis since 6 months. a Coronal CT scan (bone window) shows a
well-circumscribed mass (arrow) with ossification of variable density.
The peripheral dense portion corresponds to ivory osteoma (arrow),
whereas the central portion (asterisk) corresponds to trabecular osteoma.
b Corresponding coronal fat-saturated T1 obtained after iv. gadolinium.
The central osteoma portion (trabecular bone with marrow) enhances
after contrast material (asterisk). In the absence of CT, the ivory osteoma
portion can be misinterpreted as air. c 3D CT reconstruction: left
intraorbital extension of the ossified polylobulated mass (arrows).
Ethmoid sinus osteoma with osteoblastoma-like features in a 12-year-
old girl with right orbital pain and diplopia. d Axial CT scan (bone
window) shows a well-circumscribed polylobulated mass (arrow) with
a very dense peripheral portion and a central area of ground glass opacity.
e 3D CT reconstruction: left intraorbital extension of the ossified
polylobulated mass and involvement of the frontal bone (arrows). f
Low-power photomicrograph after complete resection (original
magnification, ×20; hematoxylin-eosin [H-E] stain) shows the central
nidus-like area (arrow) surrounded by an outer rim of sclerotic cortical
bone (asterisk). At high power, inset in f, the nidus-like portion is
composed of interconnected woven bone and osteoid, lined by plump
osteoblasts (original magnification, ×200; H-E stain)
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is caused by clonal proliferation of activated dendritic cells and
macrophages. Cells often express S100, CD1a, and CD2017/
Langerin (Fig. 3). Characteristic Birbeck granules are seen at
electron microscopy.
LCH affects both children and adults, and the male-to-
female ratio is 2:1. LCH in children typically occurs around
the age of 5 years. The disease affects the skull, orbit, mandi-
ble, palate, and long bones, as well as the lung, lymph nodes,
spleen, and the central nervous system [26, 29]. Although
craniofacial involvement is the most common manifestation
both in adults and in children, orbital lesions are more fre-
quently found in children while mandibular lesions are more
frequently seen in adults. Reactivation episodes and death are
more common in adults than in children while the 10-year
overall survival is similar in both groups [30]. Treatment mo-
dalities include surgery, radiation therapy (RT), chemotherapy
(ChT), and intralesional corticosteroid injection [31]. Low-
dose irradiation has high rates of local control and symptom-
atic improvement. However, facial asymmetry is a feared
long-term complication as RT impairs facial growth [32].
Clinical presentation in isolated maxillofacial lesions is often
non-specific and includes pain, swelling, gingival hypertro-
phy, or tooth loosening. Conventional radiographs and CT
reveal well-defined, punched-out radiolucent lesions with or
without reactive sclerosis. A soft tissue mass surrounding the
bony structures is equally present. A periosteal reaction (solid
or sunburst type) has been reported inmandibular lesions [33],
whereas a Bhole-within-a-hole^ sign and a button sequestrum
are often observed in skull involvement (Fig. 3). The hole-
within-a-hole sign corresponds to destruction of the inner
and outer tables to differing degrees, therefore resulting in
two overlying lesions of unequal size. MRI findings comprise
low signal on T1, intermediate to high signal on T2, and var-
iable contrast enhancement. ADC values appear to be higher
in LCH than in malignant tumors [33]. In conjunction with the
age of presentation, the combination of well-defined lesions
on CT, high signal on T2, strong contrast enhancement,
and ADC values >1.2 × 10−3 mm2/s is strongly evocative
of LCH, especially when patients present with multifocal
involvement or diabetes insipidus (Fig. 3). Although imag-
ing findings can be strongly evocative of LCH, histology is
mandatory.
Due to its high sensitivity, MRI is indispensable for the
primary staging of LCH, as it enables to screen the entire body
for bone involvement, to correctly assess the brain and to
guide biopsy. As contrast enhancement on CEMRI has been
shown to correlate with disease activity or perilesional inflam-
mation, MRI is equally used to evaluate treatment response
[27]. On FDG PET CT, LCH lesions are FDG avid (Fig. 3).
However, due to the small size of some lesions, the overall
sensitivity of FDG PET is limited (67%) [27]. The relatively
high specificity of FDG PET for LCH (76% as opposed to
only 47% with MRI) provides important information regard-
ing disease response. Therefore, unnecessary treatment can be
Fig. 2 Large bone sequestrum in
osteomyelitis mimicking ivory
osteoma in a 13-year-old boy with
recurrent sinusitis and right eyelid
and frontal swelling since several
months. aAxial and b coronal CT
images (bone window) show a
well-circumscribed lesion of bone
density (arrows) in the right
ethmoidal cells. The diagnosis of
ivory osteoma was suggested.
Histology (c, original
magnification, ×200; H-E stain)
and (d, original magnification,
×400; H-E stain), however
showed osteomyelitis with a large
devitalized bone fragment
corresponding to a sequestrum
(arrow in c), surrounded by
neutrophils and necrotic debris
(arrowheads in c, d)
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avoided [27]. Because combined MRI and PET CT are in-
creasingly used in pediatric LCH, it has been suggested that
PETMRI may play an important role for the initial evaluation
of pediatric LCH and for facilitated monitoring of treatment
response [16, 27, 34].
Desmoid-type fibromatosis and desmoplastic fibroma
Desmoid-type fibromatosis also called desmoid tumor or aggres-
sive fibromatosis is a rare histologically benign but locally ag-
gressive tumor arising from the fascial and musculoaponeurotic
tissues, lacking metastatic potential [35, 36]. It has an incidence
of 0.2–0.4 per 100,000 cases per year [35] and may occasionally
affect children. Desmoplastic fibroma (DF) is the intraosseous
morphological mimic of desmoid-type fibromatosis [37]. The
etiology of desmoid tumor and DF is unclear, and a genetic
predisposition (Gardener syndrome and familial adenomatous
polyposis) has been suggested. As in adults, pediatric desmoids
and DFs may occur either sporadically or in association with
familial adenomatous polyposis.
Beta-catenin is a cytoplasmic protein regulated by the ade-
nomatous polyposis coli (APC) gene and is normally located
Fig. 3 Craniofacial lesions in LCH in a 4-year-old boy with fever, failure
to thrive, and diabetes insipidus. a Conventional X-ray of lateral skull
shows a large lytic calvarial lesion (arrow). b Coronal CT scan (bone
window) shows lytic calvarial lesion with button sequestrum
(arrowhead), as well as extensive osteolysis of the sphenoid bone
(arrows). c 3D CT reconstruction: calvarial lesion in green and base of
the skull lesion in purple. d Coronal contrast-enhanced T1 shows
homogeneous and strong enhancement of the destructive lesions
(arrows). Invasion of the pterygopalatine fossa, pterygomaxillary
fissure, greater wing of the sphenoid, and adjacent dura and extension
into the nasopharynx (arrows). e Coronal FDG PET/CT image shows
focal FDG uptake of both lesions (arrows). SUVmean/SUVmax were
3.09/3.90 and 3.26/4.55, respectively. No other lesions were found in
the rest of the body neither on whole-body MRI nor on PET/CT. f
High-power photomicrograph (original magnification, ×400; H-E stain)
shows sheets of Langerhans cells with indented vesicular nuclei, admixed
with numerous eosinophils. Immunohistochemistry (inset in f, original
magnification, ×400) reveals strong reactivity of Langerhans cells to
CD1A (brown reaction product). There was also strong reactivity to
S100 protein (not shown)
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beneath the cell membrane. Mutations in the CTNNB1 gene
encoding beta-catenin and the APC gene cause beta-catenin
delocalization and accumulation in the nuclei, demonstrated
by immunohistochemistry. DFs only occasionally show beta
catenin and, contrary to desmoid-type fibromatosis of soft
tissue, do not display mutations in exon 3 of CTNNB1 [36].
Desmoid and DF have a high rate of post-surgical local recur-
rence, however no metastatic potential. According to some
authors and based on observations in our institution, DF typ-
ically affects children between 18 months and 3 years of age
and presents as a painless mass. Most DFs arise in the pelvis
and long bones whereas DF arising within the mandible, with-
in the maxilla, and in the cranium is rare [37, 38]. DF can
occur either as a solitary lesion or as a manifestation of tuber-
ous sclerosis. In fact, DF is considered to be one of the
intraoral manifestations of tuberous sclerosis rather than a co-
incidental finding. Imaging findings in DF show an expansile
intraosseous osteolytic lesion with non-aggressive looking
borders, bone remodeling or scalloping, and imaging features
suggesting a benign histology (Fig. 4). On MRI, the signal
intensity on T2-weighted and STIR images and ADC values
tend to be higher than in malignant tumors suggesting
paucicellularity and benign histology (Fig. 4). Enhancement
after intravenous gadolinium is often significant but does not
provide additional information with respect to differential di-
agnosis; it is, however, important for tumormargin delineation
in view of surgical resection. Lesions located in the calvarium
or in skull base vicinity may be strongly adherent to the dura
mater, and dural enhancement or dural thickening can be seen
at imaging necessitating coagulation or removal of the dura
during surgery. Surgical extirpation is the treatment of choice,
and RT is indicated in incompletely excised or recurrent tu-
mors. Close follow-up with cross-sectional imaging is essen-
tial as DF may recur.
Inflammatory myofibroblastic tumor
Inflammatory myofibroblastic tumor (IMT) also previously re-
ferred to as inflammatory pseudotumor, as myofibroblastoma, or
as plasma cell granuloma is an immunohistochemically diverse
entity composed ofmyofibroblasts, small lymphocytes, and plas-
ma cells. This rare and rather controversial tumor has both in-
flammatory and neoplastic characteristics including chromosom-
al alterations (translocations of the short arm of chromosome 2).
Fig. 4 Desmoplastic fibroma (DF) in a 14-month-old girl with a rapidly
growing facial mass. a Ultrasonography was non-specific revealing a
solid heterogenous hypoechoic mass with apparently no vascularization
suggesting the diagnosis of a dermoid/epidermoid cyst. bAxial CT (bone
window) shows a well-delineated lesion with smooth bony expansion
suggesting a mucocele or a benign tumor (arrow). c, d MRI findings
typical of a benign tumor: predominantly high signal on axial T2
(arrow in c) and increased diffusion on the ADC map (asterisk in d).
ADCmean = 1.9 × 10−3 mm2/s. e Photograph of gross surgical
specimen: the lesion consisted of a 3.2-cm encapsulated firm nodule. f
High-power photomicrograph (original magnification, ×200; H-E stain)
shows a paucicellular proliferation of spindle- and stellate-shaped cells
(arrow), embedded in a collagen-rich stroma (arrowhead indicates a thick
collagen bundle); a thick-walled small artery with an open lumen is seen
(asterisk). Immunohistochemistry (inset in f) shows cytoplasmic
accumulation with nuclear delocalization of beta-catenin (original
magnification, ×400, brown color). Despite morphological similarities
with desmoid-type fibromatosis, Sanger sequencing revealed no
mutation in the exon 3 of the CTNNB1 gene encoding beta-catenin
consistent with the diagnosis of desmoplastic fibroma
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The rearrangement of the anaplastic lymphoma kinase (ALK)
gene at chromosome 2p23, which can be demonstrated by fluo-
rescence in situ hybridization, is now regarded as pathognomonic
for the definitive diagnosis. More than 50% of IMTs occur in
children and adolescents, and there is a strong predilection for the
lung, abdomen, retroperitoneum, and extremities [39]. In theHN,
IMTs affect the orbit, larynx, oral cavity and oropharynx,
parapharyngeal space, and thyroid gland. IMTs may also affect
the paranasal sinuses, and on rare occasions, progression to
overtly sarcomatous morphology or distant metastases can
occur [40]. Because IMTs also tend to recur and because of
the rare potential for malignant transformation, IMTs are clas-
sified as tumors with intermediate biological potential. IMTs
often present as rapidly growing painless masses, and there are
no systemic signs. Lesions arising in the paranasal sinuses and
pterygopalatine fossa have a more aggressive behavior
(Fig. 5) [41, 42].
Cross-sectional imaging is indispensable for treatment
planning and for the assessment of precise tumor spread. In
addition, it has been suggested that CT and MRI may help to
differentiate between aggressive sinonasal malignancy and
IMT. IMTs are most often lobular or spherical masses with a
smooth, regular rim. The tumors are hyperdense on non-
contrast-enhanced CT (NECT) and hypointense on T2, and
they display strong enhancement after intravenous contrast
material (Fig. 5). It has been suggested that the combination
of hypointense signal on T2-weighted images and high ADC
values is typical MRI features of IMT allowing a correct pre-
sumptive diagnosis [43]. Bone remodeling and thin peripheral
calcification are further characteristics. However, when tu-
mors grow very large, hemorrhage and necrosis may lead to
heterogenous signal intensity on T2 rendering distinction from
malignant lesions more difficult. The management of these
tumors is challenging, and there are no generalized treatment
Fig. 5 Inflammatorymyofibroblastic tumor (IMT) in a 6-year-old girl with
a rapidly growing mass and facial deformity. A rhabdomyosarcoma was
suspected clinically. a Axial CT scan (bone window) shows an spherical
midfacial lesion remodeling the facial skeleton, with a thin peripheral
calcified rim (arrows), hypertelorism, and exophthalmos. Three-
dimensional CT reconstruction (inset in a) shows Bsoap bubble
appearance^ with remodeling of the nasal cavity. b Axial T2 depicts
multiple lobular predominantly hypointense tumor compartments
(asterisk). Note that the T2 signal is quite homogeneous within each
individual tumor compartment. c Axial T1 shows no areas of hemorrhage.
d T1 post-contrast reveals strong homogenous enhancement within the
different compartments. e Gross pathology: nodular fleshy to
firm nodule. f1 High-power photomicrograph (original magnification,
×200; H-E stain) showing proliferation of spindle cells arranged in a
vaguely fascicular pattern, surrounding glands. At higher magnification
(f2), mildly atypical myofibroblasts with prominent nucleoli (arrow); the
accompanying inflammatory infiltrate is mainly composed of lymphocytes
and plasma cells. f3On immunohistochemistry, the myofibroblastic spindle
cells show strong cytoplasmic immunoreactivity for ALK protein (brown
color), typical for IMT
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protocols, especially for large lesions located in close proxim-
ity to vital structures. To date, complete surgical excision,
corticosteroid treatment, or ChT with an ALK inhibitor in
refractory cases is recommended, corticosteroid treatment be-
ing the most common treatment modality in smaller lesions.
Juvenile ossifying fibroma
Juvenile ossifying fibroma is a rare benign fibro-osseous neo-
plasm usually seen in the craniofacial bones. It has the poten-
tial for aggressive growth as the denomination previously
used by the WHO (juvenile aggressive ossifying fibroma)
implies. Two distinct histological variants have been de-
scribed: juvenile psammomatoid ossifying fibroma (JPOF)
and juvenile trabecular ossifying fibroma (JTOF) [44, 45].
Both neoplasms have different age distributions, different pre-
dilection sites, and different radiologic features. While JPOF
is more common in adults in the paranasal sinuses (ethmoid
and sphenoid), JTOF is predominantly seen in children
between 8 and 10 years of age with a predilection for the
alveolar ridge of the maxilla. JPOF often presents with major
facial deformation and occasionally hypertelorism due to
bony expansion (Fig. 6). Histologically, JPOF shows numer-
ous psammomatous calcifications, which account for the
ground glass opacity on CT. The radiologic aspect is charac-
teristic and allows the correct diagnosis in most cases (Fig. 6).
JPOF presents as an expansile mass with well-defined sclerot-
ic borders, with ground glass opacity, and with areas of central
radiolucency. These radiolucent areas have fluid-fluid levels
easily seen on MRI. The tumor shows displacement rather
than infiltration of soft tissues, and the associated bony expan-
sion has a typical spherical configuration (Fig. 6). The differ-
ential diagnosis is fibrous dysplasia (FD). However, in con-
trast to JPOF, FD typically shows ill-defined borders blending
with the normal bone and the overall shape of the affected
bone is preserved. In most patients with FD, CT reveals char-
acteristic bony expansion with a Bground glass^ appearance or
mixed radiolucency, widened diploic space with outer table
Fig. 6 Juvenile psammomatoid ossifying fibroma (JPOF) in a 10-year-
old girl with periorbital swelling and hypertelorism. a Axial CT scan
(bone window) shows an expansile, well-circumscribed spherical lesion
with ground glass opacity and rounded cystic areas (asterisks). Invasion
of ethmoid and sphenoid sinuses and orbits. Lateral displacement of the
right globe with proptosis. b 3D CT reconstruction: lesion in blue and
cystic areas in yellow. c Axial T2 reveals that the solid parts with ground
glass opacity on CT have a very low T2 signal. The cystic areas have
fluid-fluid levels (arrow). d Axial T1 shows homogenous low signal of
the mass matrix with increased signal in the cystic components indicating
proteinaceous or hemorrhagic content. e Axial post-contrast T1 shows
moderate homogenous matrix enhancement and rim enhancement of
the cystic areas. f High-power photomicrograph (original magnification,
×200; H-E stain) shows small concentric lamellated ossicles resembling
psammoma bodies surrounded by a thick irregular collagenous rim,
embedded in a fibroblastic stroma
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displacement or bubbling skull vault lesions. On PET CT,
both IPOF and FDmay show high FDG uptake, thereby mim-
icking bone metastases or other aggressive bone lesions [46].
However, the characteristic CTaspect and—if necessary—the
high ADC values help to avoid misinterpretation.
Therefore, correlation between FDG uptake on PET
CT and morphologic CT or MRI features is essential.
As treatment consists of surgery, cross-sectional imaging
plays an important role not only for diagnosis but also
for precise planning of resection. Multimodality image
fusion and 3D volume rendering are helpful for surgical
resection.
Ewing sarcoma
Ewing sarcoma (ES) is a rare primary bone malignancy
mainly affecting children and adolescents, most cases oc-
curring between 10 and 20 years of age [47–49]. It arises in
the medullary cavity of bone and invades the Haversian
system. The tumor is composed of narrow sheets of small,
round, and densely packed cells with scanty cytoplasm,
showing varying degrees of neuroectodermal differentia-
tion. These small blue rounded cells are glycogen positive,
and on electron microscopy, features of neural differentia-
tion are found. The origin of ES is a subject of much debate,
and it is not yet clear whether ES arises from primitive
neuroectodermal cells or from mesenchymal stem cells
[49]. In almost all ES cases, there is a characteristic recip-
rocal chromosomal translocation between the EWSR1 gene
and a gene of the ES tumor family of transcription factors.
The ES tumor family comprises ES, neuroepithelioma, pe-
ripheral primitive neuroectodermal tumor, and Askin tu-
mor. As a highly malignant tumor, ES has an early metasta-
tic potential to the lungs, liver, bone marrow, and other
organs [48]. Only 2% of all ES cases arise in the skull and
face, and involvement of the zygoma is very rare [47].
Clinical presentation in the HN is non-specific and includes
pain, facial swelling, palpable mass, fever, and increased
erythrocyte sedimentation rate (ESR). However, on cross-
sectional imaging, ES presents as a large poorly defined
lesion with extension into the surrounding soft tissues.
Permeative osteolysis, irregular areas of sclerosis and an
onion skin periosteal reaction are common on CT.
Sunburst appearance, Codman triangle, bony expansion,
and the presence of a soft tissue mass are further features
suggesting an aggressive tumor (Fig. 7). On T2-weighted
and contrast-enhanced T1-weighted images, ES displays
heterogeneous signal, and on DWI, there is marked restric-
tion of diffusion with low ADC values (<0.9–1 × 10−3 mm2/
s) in keeping with the malignant nature of the tumor
(Fig. 7). In some ES cases of the jaws, distinction from
chronic osteomyelitis (OM) can be challenging on the basis
of clinical findings (demographics, history, physical
examination, and laboratory findings) and on the basis of
cross-sectional imaging features. As recently suggested,
other than ethnicity (African Americans are more likely to
have OM than ES), no clinical feature improves diagnostic
accuracy while among the morphologic features (without
DWI), only the presence of a soft tissue mass at MRI ap-
pears to be significantly associated with ES [50]. On FDG
PET CT, both OM and ES show increased tracer uptake
within the bone and within the surrounding soft tissues
due to increased glucose metabolism in inflammatory and
malignant tissue, respectively.
The metastatic workup in ES includes whole-body MRI
with DWI and FDG PET CT. Treatment consists of ChT
with additional surgery depending on the location of the
tumor. Survival depends upon the presence of distant me-
tastases, primary tumor location, and red blood cell count
[51]. The use of DWI is important not only for diagnostic
and staging purposes but also for the monitoring of treat-
ment response and for personalized therapeutic approaches.
For example, involved compartment irradiation detected by
whole-body MRI combined with high-dose ChT and stem
cell rescue in ES patients with multiple primary bone me-
tastases appears to significantly improve survival at 5 and
10 years after diagnosis in comparison to ES patients treat-
ed according to the standard protocol of the European
Intergroup Cooperative Ewing Sarcoma Study-92 [52].
On follow-up after neoadjuvant ChT, good responders typ-
ically show a significant and early increase of ADC values
corresponding to treatment-related tumor necrosis while
morphologic features including contrast-to-noise ratio on
T2 and on gadolinium-enhanced T1 tend to remain similar.
A recent study found that 3D tumor measurements are bet-
ter predictors of the therapeutic response in ES than in one-
dimensional (1D) Response Evaluation Criteria in Solid
Tumors (RECIST) and 2D measurements (WHO criteria);
3D measurements also showed a significantly higher cor-
relation with clinical outcomes [53].
Although the mean radiation dose of patients examined
with FDG PET CT for staging and treatment of ES is on
average 23% higher than for patients not examined with
PET CT [54], whole-body PET CT has a relevant impact
on therapy planning in children outperforming conven-
tional imaging modalities (US, CT, bone scintigraphy,
and morphologic MRI). FDG PET and conventional im-
aging modalities appear to be equally effective in the de-
tection of primary tumors; however, PET is superior for
the detection of lymph node metastases and bone metas-
tases, whereas CT is more reliable for the depiction of
lung metastases [55]. Quantification of FDG uptake with
SUV may also be able to predict prognosis of children
with ES: patients with a pretreatment SUVmax ≤5.8 have
been shown to survive significantly longer than those with
a SUVmax >5.8 [56].
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Primary intraosseous lymphoma
Non-Hodgkin’s lymphoma (NHL) tends to involve extranodal
sites more often than Hodgkin’s lymphoma [57, 58]. The most
common pediatric NHL types in the HN include diffuse large
B cell-type NHL, lymphoblastic lymphoma, and Burkitt lym-
phoma. Epstein-Barr virus (EBV) infection in early life is
associated not only with Burkitt lymphoma but also with
Hodgkin’s lymphoma, nasopharyngeal carcinoma, and post-
transplantation lymphoproliferative disease [58]. Endemic
Burkitt lymphoma, which is mainly seen in equatorial
Africa, has a 95% rate of association with EBV and is often
linked to coinfection with Plasmodium falciparum [58].
Sporadic Burkitt lymphoma is associated with EBV infection
in up to 30% of cases, and HIV-associated Burkitt lymphoma
is positive for EBV in up to 50%.Whenever lymphoma arises
within a bone without nodal or visceral involvement within
6 months of presentation, it is named primary intraosseous
lymphoma (PIL) [57]. According to the literature, PIL consti-
tutes about 3% of all malignant bone tumors and 5% of all
extranodal lymphomas. Most PILs are Burkitt lymphomas.
PIL is rare in children under 10 years of age. Pediatric PIL
most often involves the lower extremities whereas mandibular
or maxillary involvement is rare. Unfortunately, most PILs
affecting the jaws are often misdiagnosed, as patients may
present with tooth pain or tooth mobility, gingival swelling,
Fig. 7 Ewing sarcoma (ES) of the maxilla: characteristic findings in a 5-
year-old girl with gradually progressing indurated swelling of the left
cheek. a Axial CT scan (bone window) shows a lytic lesion with
sunburst-type periosteal reaction and bone expansion (arrow). Three-
dimensional CT reconstruction (inset in a) illustrates invasion of the left
maxillary sinus, orbital floor, zygomatic arch, and maxillary alveolar
ridge. The tumor is rendered in yellow. b Axial T2 shows intermediate
tumor signal with small areas of necrosis (bright areas, arrowhead),
invasion of the left maxillary sinus, and zygomatic arch (arrow), as well
as invasion of the suprazygomatic masticator space. c Axial T1 depicts
non-specific intermediate signal of the mass with invasion of the
temporalis muscle (arrow). d Axial post-contrast fat-saturated T1
reveals inhomogeneous and strong enhancement with small necrotic
areas (arrow). e Restricted diffusion (asterisk) with very low signal on
the ADC map (ADC = 0.6 × 10−3 mm2/s). f High-power
photomicrograph (original magnification, ×400; H-E stain) shows that
the tumor is composed of sheets of undifferentiated small round blue
cells, invading bone (asterisk). Immunohistochemistry (not shown)
reveals membranous reactivity to CD99 (O13 mouse monoclonal
antibody). Fluorescence in situ hybridization (FISH) shows EWSR1 gene
rearrangement (inset in f, arrows; Vysis®, LSI dual-color break-
apart probe FISH probe); translocation results in the separation of a pair
of green and orange signals. Reverse transcription polymerase chain
reaction (RT-PCR) uncovered a t(11;22)(q24;q21)EWSR1-FLI1
translocation, thereby further confirming ES
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and bleeding, which canmimic periodontal disease. The initial
wrong diagnosis is often followed bymultiple root canal treat-
ments or extraction of wisdom teeth. However, the diagnosis
of maxillofacial PIL can be strongly suggested by radiologists
on the basis of MRI findings, thereby contributing to a rapid
diagnosis (Fig. 8). On NECT, PIL demonstrates diffuse per-
meative osteolysis, cortical destruction, and juxtacortical soft
tissue masses. The marrow space of the affected bone has low
signal intensity on T1 and intermediate signal intensity on T2.
On contrast-enhanced T1, PIL displays homogenous and dif-
fuse enhancement. In association with very low ADC values
(ADC = 0.4–0.7 × 10−3 mm2/s), the diagnosis can be sug-
gested with a high degree of confidence, therefore prompting
rapid biopsy. Whole-body staging is necessary for the diagno-
sis of PIL, as involvement of other sites needs to be ruled out
and PIL needs to be distinguished from bone deposits caused
by disseminated NHL. ChT is the treatment of choice, and
prognosis is usually good. In a recent study dealing with
primary pediatric lymphoma of the bone, post-treatment fol-
low-up with conventional morphologic imaging (without
DWI) did not alter clinical management in the absence of
symptoms, in particular also due to the lack of correlation
between osseous changes after treatment on conventional
morphologic images and clinical outcome [59]. Only FDG
PET CT proved capable of demonstrating metabolic imaging
changes consistent with the clinical response to treatment [59].
The diagnosis of PIL is, therefore, most often complemented
by FDG PET CT or more recently by FDG PET MRI.
Metastases to the facial bones
Metastases to the facial bones are very rare in children. They
typically occur in widespread disease, and the primary tumor
is most often known. However, whenever bone metastases
without a known primary tumor are considered in the
Fig. 8 Primary intraosseous Burkitt lymphoma in a 14-year-old boy with
gingival and vestibular swelling and increased molar teeth mobility. a
Clinical aspect: submucosal swelling with intact mucosa. Courtesy:
Andrej Terzic, MD, Clinic for maxillofacial surgery, University
Hospital Geneva. b Axial contrast-enhanced CT shows diffuse marrow
infiltration bilaterally (arrows) and absent bone trabeculae. c Axial T2
reveals homogeneous signal (arrows) and root resorption on the right.
Note extraosseous bilateral spread (asterisk). d Very low ADC values
(0.3–0.5 × 10−3 mm2/s) (asterisk) typical of lymphoma. e Axial PET
MRI (PET fused with T2) shows high intraosseous and extraosseous
FDG uptake with very high SUVs (SUVmean/SUVmax = 14.32/19.98)
(arrows). f High-power photomicrograph (original magnification, ×200;
H-E stain) shows sheets of undifferentiated medium-sized lymphoid cells
and intermingled tangible body macrophages, creating a characteristic
Bstarry sky^ appearance. Upon immunohistochemical evaluation, the
tumor cells showed reactivity to CD20, CD10, CD79A, BCL6, and
MYC, and the proliferation index was close to 100% (not shown). A
fluorescent in situ hybridization (FISH) assay (inset in f) confirmed
MYC gene rearrangement. Translocation results in the separation of a
pair of green and orange signals (arrows) (Vysis®, LSI dual-color
break-apart probe)
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differential diagnosis on the basis of cross-sectional imaging,
possible primaries would include neuroblastoma, ES,
angiosarcoma, retinoblastoma, NHL, and leukemia.
Neuroblastoma
Neuroblastoma (NB) is the most common solid childhood
malignancy and accounts for about 8% of all childhood can-
cers in industrialized countries. It typically occurs in infants
and children under the age of 5, most cases being seen under
the age of 2 years. The tumor arises from pluripotent sympa-
thetic cells located in the sympathetic ganglia, adrenal medul-
la, and other sites [60]. In infants, most NBs arise in the chest,
whereas in children, most NBs arise in the abdomen. NBs
have many chromosomal and molecular abnormalities, such
as amplification of the MYCN oncogene (more common in
advanced stage disease); overexpression of the HRAS onco-
gene (more common in lower-stage disease); chromosome 1p
deletion; allelic losses of chromosomes 11q, 14q, and 17q;
and variable expression of neurotrophin receptor gene prod-
ucts. Prognosis in NB depends upon the age of presentation,
stage, and molecular factors. Patients with low to intermediate
risk NB have an excellent prognosis while those with high-
risk tumors have a very poor survival despite intensive ChT,
RT, and autologous bone marrow transplantation [61]. Most
NB lesions seen in the HN are metastases from abdominal
NB. Unfortunately, metastatic disease is very common among
children older than 18 months of age. According to a recent
study, NBwas the most common tumor with metastases to the
jaws in the age group ranging from 4 months to 16 years and
metastasis to the maxilla or mandible was found to be the first
metastatic site in half of these patients [62, 63]. On CT and
Fig. 9 Mandibular metastasis from neuroblastoma (NB) in a 5-year-old
girl with fatigue and localized right mandibular swelling. Treated for
abdominal NB. a Axial CT scan (bone window) shows extensive
osteolysis of the mandibular angle with ill-defined, destructive margins,
overlying soft tissue mass, expanded cortex with Codman triangle typical
of an aggressive bone lesion (arrows). Three-dimensional CT
reconstruction (inset in a) illustrates the relationship between the tumor
(green), inferior alveolar nerve canal (gray), and teeth (blue). b Axial T2
reveals polypoid lesion with intermediate signal (arrows) and major
extraosseous involvement. Invasion of the masseter muscle. c
Homogeneous non-specific enhancement on axial post-contrast fat-
saturated T1. d Restricted diffusion with very low signal on the ADC
map (asterisk) (ADC = 0.54 × 10−3 mm2/s). Imaging findings are
characteristic of a highly malignant tumor and—in this clinical
context—suggest metastasis from NB. Whole-body 123I–MIBG
SPECT/CT (e) revealed further calvarial and skull base metastases. f
High-power photomicrograph (original magnification, ×400; H-E stain)
shows poorly differentiated neuroblasts surrounded by small amounts
of neuropil (finely fibrillar and eosinophilic matrix corresponding to
neuri t ic processes) and characterist ic reactivi ty to NB84
on immunohistochemistry (inset in f)
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MRI, NB metastases to the maxillofacial skeleton have all
imaging characteristics of aggressive tumors (Fig. 9): diffuse
permeative or moth-eaten osteolysis, cortical destruction,
poorly delineated soft tissue masses with or without calcifica-
tion, and areas of necrosis. On MRI, NB shows intermediate
signal intensity on T2, strong enhancement after intravenous
administration of gadolinium, and low ADC values in the
solid portions. Areas of necrosis are common.
In addition to CT and MRI, metaiodobenzylguanidine la-
beled to iodine123 (123I MIBG) scintigraphy, FDG, and fluoro-
dihydroxyphenylalanine (FDOPA) PET CT are used for the
assessment of primary and metastatic NB. 123I MIBG is a
specific guanethidine derivative that is taken up by the norepi-
nephrine transporter (NET) on NB cells. The reported sensi-
tivity of 123I MIBG scintigraphy for the detection of NB and
metastases varies from 67 to 100% with a 10% rate of false-
negative evaluations, as the tumor may not show tracer accu-
mulation [64]. For these patients, FDG PET CT has been
recommended for staging purposes and for assessing response
to therapy. However, data on the performance of PET CT in
comparison to other imaging modalities are currently quite
limited. Nevertheless, FDG and FDOPA PET CT can be used
to stratify patients with NB into risk groups [65]. FDG
SUVmax ≥3.31 and FDOPA SUVmax <4.12 have been iden-
tified as ultra-high-risk features capable of distinguishing the
most unfavorable genomic types (MYCN amplification and
segmental chromosomal alterations) with a sensitivity of 81%
and a specificity of 93% [65]. Therefore, the ratio between
FDG and FDOPA uptake may complement the current risk
stratification systems of NB [65]. Treatment of symptomatic
metastases to the facial bones, in particular the mandible, is
often done with short intensive RT courses to palliate pain
[66]. Short RTcourses are more suitable for the young patients
especially if general anesthesia is needed.
Conclusion
Interpretation of imaging findings in children with non-
odontogenic tumors of the facial skeleton is challenging.
Multimodality imaging allows for detailed evaluation of ana-
tomic extent and increases diagnostic confidence. It also con-
tributes important information for prognosis and risk stratifica-
tion and enhances pretherapeutic assessment, as well as moni-
toring of patients after treatment. This review article summa-
rizes multimodality imaging features of these rare tumors.
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